Project Grant R01CA309621
Award Date 5/1/26
Completion Date 4/30/31
Dollars Obligated $402K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
- Federal Grant Award Summary The University of Texas Southwestern Medical Center received a $639,514 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) effective June 1, 2026, through May 31, 2031. This five-year research initiative funds mechanistic characterization studies of benzothiazepinone compounds, specifically MM17, which inhibit NVL (a critical AAA+ adenosine triphosphatase enzyme involved in ribosomal subunit...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Texas at Austin a $2.59 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2029. The award supports research to develop a novel cancer immunotherapy approach targeting immune-excluded or "cold" tumors that typically demonstrate poor response to immune checkpoint therapy. The project focuses on demonstrating that degradation of...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $421,685 Project Grant to The Regents of the University of California, San Francisco under the Cancer Biology Research program (CFDA 93.396) for research activities spanning August 8, 2025 through July 31, 2027. This award funds a discovery-focused research initiative investigating functional immune niches within the tumor microenvironment (TME) that support effective cancer immunotherapy responses. The primary deliverable...
- Federal Grant Award Summary The National Cancer Institute awarded a $404,972 Project Grant to The University of Texas Health Science Center at San Antonio under the Cancer Biology Research program (CFDA 93.396) for a two-year project period beginning August 1, 2025 and concluding July 31, 2027. This award supports fundamental research investigating ribosomal ribonucleic acid (rRNA) modification, ribosome composition, and specialized translation mechanisms in glioblastoma, the most common and...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The University of Texas Southwestern Medical Center a Project Grant of $426,828 under the Cancer Treatment Research program (CFDA 93.395) on May 4, 2026, with a completion date of April 30, 2028. This research grant supports the validation and translation of findings regarding JUMONJI KDM5 histone demethylase enzymes and their role in mediating resistance to CDK4/6 inhibitors in estrogen receptor-positive (ER+) breast...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $421,685 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The University of Texas MD Anderson Cancer Center, effective August 1, 2025, through July 31, 2027. This award supports pan-cancer analysis of convergent immunoglobulins from tumor-infiltrating B cells (TIL-B), with the primary deliverable being the identification and characterization of shared B cell receptors (BCR) and antibodies across...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $616,715 to The University of Texas MD Anderson Cancer Center, with an award date of August 11, 2025 and completion date of July 31, 2030. This award supports research under the Cancer Treatment Research program (CFDA 93.395), which develops and evaluates improved methods of cancer treatment through fundamental and applied laboratory and clinical research. The funded research centers on the...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $663,340 Project Grant to the University of California, Berkeley under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research on regulatory T cell-mediated suppression of tumor elimination. The award, made on August 27, 2025 with completion targeted for July 31, 2030, will fund investigations into how the local ablation of intra-tumoral regulatory T cells (IT-Tregs) mobilizes natural killer...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $421,685 project grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded August 1, 2025, with a completion date of July 31, 2027. This award supports research investigating the LIFR-LCN2 pathway as a novel mechanism of immune suppression in hepatocellular carcinoma (HCC). The research aims to elucidate how loss of LIFR upregulates LCN2, leading to...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $596,501 to The University of Texas Southwestern Medical Center under the Cancer Biology Research program (CFDA 93.396) on June 20, 2026, with completion targeted for May 31, 2031. This award funds fundamental research investigating the molecular mechanisms of translocation renal cell carcinoma (TRCC), a particularly aggressive kidney cancer subtype that predominantly affects children and adolescents and...